A new form of deep brain stimulation (DBS) that adapts in real time to a patient's walking patterns is helping people with Parkinson's disease improve their gait and reduce falls. Unlike traditional DBS devices that deliver fixed stimulation, this adaptive system detects neural signals corresponding to different phases of walking and automatically adjusts stimulation within fractions of a second, much like a cardiac pacemaker responds to the heart's rhythm.

Why Is Walking So Hard for Parkinson's Patients?

Over 10 million people worldwide live with Parkinson's disease, a neurological condition that affects movement and motor control. While conventional DBS has been shown to improve certain symptoms like tremor, stiffness, and slowness, it has had limited effects on walking. Researchers think this is because walking is a highly dynamic behavior that requires precise timing across both sides of the body. A person's gait is constantly changing, and the fixed stimulation pattern delivered by conventional DBS doesn't reflect the rapid coordination among the brain, spinal cord, and muscles required to walk.

This gap in treatment has made walking one of the most disabling and hard-to-treat symptoms of Parkinson's disease. Many patients experience falls and loss of mobility, which significantly impacts their quality of life and independence.

How Does Adaptive Deep Brain Stimulation Work?

Scientists at the University of California, San Francisco (UCSF) developed a personalized adaptive DBS (aDBS) system that fundamentally changes how the device responds to the patient's needs. The implanted system detects specific neural signals corresponding to different phases of gait, including whether the left or right leg is swinging, and automatically adjusts stimulation within fractions of a second.

One of the most interesting findings was that while many patients exhibited changes within similar frequency ranges, the optimal signals and recording locations varied substantially between individuals. In some patients, the most informative signals came from the cortex, while in others they came from the basal ganglia, the deep brain structures involved in movement control.

"This highlights an important principle for future neuromodulation therapies: there is unlikely to be a single biomarker that works for everyone. Instead, we will probably need personalized approaches that identify and respond to each patient's unique neural signatures," said Doris D. Wang, a neurosurgeon at UCSF.

Doris D. Wang, Neurosurgeon at UCSF

What Were the Results?

In laboratory testing, the aDBS system improved gait symmetry and reduced variability in walking patterns. Participants reported fewer falls while maintaining overall control of Parkinson's symptoms when using the system in their daily lives. Perhaps most tellingly, when patients experienced both therapies at home in a blinded fashion, those who remained in the study chose to continue using adaptive DBS when given the option for more than a year after the trial ended.

The study involved five people, so larger studies are needed to understand how these algorithms perform across diverse patient populations, different stages of Parkinson's disease, and varying gait impairments. However, the early results suggest a promising new direction for treating one of Parkinson's most challenging symptoms.

Steps to Bringing This Technology to Patients

• Simplify the Hardware: Future versions will need to achieve similar performance using commercially available hardware and signals that can be recorded from routinely implanted electrodes, rather than the additional research electrodes used in the current study.
• Automate Biomarker Discovery: For this technology to become broadly practical, devices will need to automatically discover and adapt to an individual's neural signatures with minimal clinician intervention, rather than requiring detailed in-clinic testing.
• Conduct Larger Studies: Researchers plan to conduct larger multicentre studies to evaluate long-term safety, efficacy, and patient benefit across different populations and disease stages.

What's Next for Adaptive Brain Stimulation?

The underlying concept extends far beyond walking. Parkinson's disease affects many domains of function, including sleep, cognition, mood, and other motor symptoms. In principle, adaptive stimulation could be designed to detect neural signatures associated with these states and deliver therapy only when needed.

The platform also provides a framework for treating brain disorders using real-time feedback from the nervous system itself. Similar approaches are already being explored for conditions such as obsessive-compulsive disorder, depression, epilepsy, chronic pain, and other neuropsychiatric disorders. This study represents part of a larger shift toward intelligent neuromodulation systems that continuously adapt to a patient's changing brain state.

Meanwhile, research into Parkinson's treatment continues on multiple fronts. A multidisciplinary analysis from the University of Florida examined why some patients are not approved for DBS therapy, finding that cognitive risk concerns, incongruent expectations for surgery, and psychiatric concerns were the three most common reasons for candidacy failure among 1,758 patients evaluated. This underscores the importance of careful patient selection and comprehensive evaluation before recommending invasive procedures like DBS.

As researchers work to translate adaptive DBS findings into practical technologies for widespread clinical use, the promise of personalized, responsive brain stimulation offers hope for millions of people living with Parkinson's disease and other movement disorders.